Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

NCT07136714 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce symptoms of depression in adults who have major depressive disorder and are also overweight or obese.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 116 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-09 · est. completion 2027-09

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT07136714 ↗

Description as written by the study sponsor.

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing overweight or obesity. The treatment will be an add-on treatment to the patient's usual medication. The investigators hypothesize that adjunctive treatment with semaglutide, will lead to a significant improvement in mood compared to placebo in patients with MDD and overweight or obesity. The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from start to follow-up after 26 weeks. The MDI measures the extent to which symptoms of depression have been present in the past two weeks.

Treatments tested

Semaglutide Injectable Product Drug

Semaglutide (Wegovy) once-weekly injection s.c
Placebo Drug

Placebo (BD Posiflush) once-weekly injection s.c

Main thing measured	Change in depressive symptoms
Sponsor	Nordsjaellands Hospital
Conditions studied	Major Depressive Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07136714 ↗